EDP Sciences logo
Submit your paper
Search
Menu
All issues Volume 51 / No 4 (December 2019) J Extra Corpor Technol, 51 4 (2019) 201-209 References
Free Access
Issue
J Extra Corpor Technol
Volume 51, Number 4, December 2019
Page(s) 201 - 209
DOI https://doi.org/10.1051/ject/201951201
Published online 15 December 2019
  1. Jencks SF, Williams MV, Coleman EA Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med. 2009;360:1418–28. [CrossRef] [PubMed] [Google Scholar]
  2. Stone J, Hoffman GJ Medicare hospital readmissions: Issues, policy options and PPACA. Congressional Research Service, Washington, DC; 2010:1–37. [Google Scholar]
  3. Hannan EL, Zhong Y, Krumholz H, et al. 30-day readmission for patients undergoing percutaneous coronary interventions in New York state. JACC Cardiovasc Interv. 2011;4:1335–42. [CrossRef] [PubMed] [Google Scholar]
  4. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics–2012 update: A report from the American Heart Association. Circulation. 2012;125:e2–220. [CrossRef] [Google Scholar]
  5. Morgan JM, Gray HH, Clague JC, et al. Coronary arterial surgery in the elderly: Its effect in the relief of angina. Int J Cardiol. 1989;23:327–33. [CrossRef] [PubMed] [Google Scholar]
  6. Kremneva LV, Suplotov SN Risk factors and in-hospital outcomes of acute kidney injury that developed after coronary artery bypass grafting in patients with stable angina. Ter Arkh. 2018;90:48–52. [PubMed] [Google Scholar]
  7. Ferraris VA, Ferraris SP, Harmon RC, et al. Risk factors for early hospital readmission after cardiac operations. J Thorac Cardiovasc Surg. 2001;122:278–86. [CrossRef] [PubMed] [Google Scholar]
  8. Litmathe J, Kurt M, Feindt P, et al. Predictors and outcome of ICU readmission after cardiac surgery. Thorac Cardiovasc Surg. 2009;57:391–4. [CrossRef] [PubMed] [Google Scholar]
  9. Rockx MA, Fox SA, Stitt LW, et al. Is obesity a predictor of mortality, morbidity and readmission after cardiac surgery? Can J Surg. 2004;47:34–8. [PubMed] [Google Scholar]
  10. Tam DY, Fang J, Tran A, et al. A clinical risk scoring tool to predict readmission after cardiac surgery: An Ontario administrative and clinical population database study. Can J Cardiol. 2018;34:1655–64. [CrossRef] [PubMed] [Google Scholar]
  11. Magnus PC, Chaisson K, Kramer RS, et al. Causes of 30-day readmission after cardiac surgery in Northern New England. Circulation. 2011;124(Suppl 21):A13474. [Google Scholar]
  12. Brown JR, Thiessen-Philbrook H, Goodrich CA, et al. Are urinary biomarkers better than acute kidney injury duration for predicting readmission? Ann Thorac Surg. 2019;107:1699–705. [CrossRef] [PubMed] [Google Scholar]
  13. Brown JR, Stabler ME, Parker DM, et al. Biomarkers improve prediction of 30-day unplanned readmission or mortality after paediatric congenital heart surgery. Cardiol Young. 2019;29:1051–6. [CrossRef] [PubMed] [Google Scholar]
  14. Parker DM, Everett AD, Stabler ME, et al. Biomarkers associated with 30-day readmission and mortality after pediatric congenital heart surgery. J Card Surg. 2019;34:329–36. [CrossRef] [PubMed] [Google Scholar]
  15. Preeshagul IR, Van Besien K, Mark TM Controversies in multiple myeloma: To transplant or not? Curr Hematol Malig Rep. 2014;9:360–7. [CrossRef] [PubMed] [Google Scholar]
  16. Frantz S, Bauersachs J, Kelly RA Innate immunity and the heart. Curr Pharm Des. 2005;11:1279–90. [CrossRef] [PubMed] [Google Scholar]
  17. Tarnok A, Emmrich F Immune consequences of pediatric and adult cardiovascular surgery: Report of the 7th Leipzig workshop. Cytometry B Clin Cytom. 2003;54:54–7. [CrossRef] [Google Scholar]
  18. Jones SA, Fraser DJ, Fielding CA, et al. Interleukin-6 in renal disease and therapy. Nephrol Dial Transplant. 2015;30:564–74. [CrossRef] [PubMed] [Google Scholar]
  19. Nechemia-Arbely Y, Barkan D, Pizov G, et al. IL-6/IL-6R axis plays a critical role in acute kidney injury. J Am Soc Nephrol. 2008;19:1106–15. [CrossRef] [PubMed] [Google Scholar]
  20. Peranteau WH, Zhang L, Muvarak N, et al. IL-10 overexpression decreases inflammatory mediators and promotes regenerative healing in an adult model of scar formation. J Invest Dermatol. 2008;128:1852–60. [CrossRef] [PubMed] [Google Scholar]
  21. Stenvinkel P, Ketteler M, Johnson RJ, et al. IL-10, IL-6, and TNF-α: Central factors in the altered cytokine network of uremia—The good, the bad, and the ugly. Kidney Int. 2005;67:1216–33. [CrossRef] [PubMed] [Google Scholar]
  22. Curtis JP, Schreiner G, Wang Y, et al. All-cause readmission and repeat revascularization after percutaneous coronary intervention in a cohort of medicare patients. J Am Coll Cardiol. 2009;54:903–7. [CrossRef] [PubMed] [Google Scholar]
  23. Brown JR, Furnary AP, Mackenzie TA, et al. Does tight glucose control prevent myocardial injury and inflammation? J Extra Corpor Technol. 2011;43:144–52. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  24. Brown JR, Hernandez FJr, Klemperer JD, et al. Cardiac troponin T levels in on- and off-pump coronary artery bypass surgery. Heart Surg Forum. 2007;10:E42–6. [Google Scholar]
  25. Brown JR, Landis RC, Chaisson K, et al. Preoperative white blood cell count and risk of 30-day readmission after cardiac surgery. Int J Inflam. 2013;2013:781024. [PubMed] [Google Scholar]
  26. Brown JR, MacKenzie TA, Dacey LJ, et al. Using biomarkers to improve the preoperative prediction of death in coronary artery bypass graft patients. J Extra Corpor Technol. 2010;42:293–300. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  27. Brown JR, Parikh CR, Ross CS, et al. Impact of perioperative acute kidney injury as a severity index for thirty-day readmission after cardiac surgery. Ann Thorac Surg. 2014;97:111–7. [CrossRef] [PubMed] [Google Scholar]
  28. Couper KN, Blount DG, Riley EM IL-10: The master regulator of immunity to infection. J Immunol. 2008;180:5771–7. [CrossRef] [PubMed] [Google Scholar]
  29. Greenberg JH, Whitlock R, Zhang WR, et al. Interleukin-6 and interleukin-10 as acute kidney injury biomarkers in pediatric cardiac surgery. Pediatr Nephrol. 2015;30:1519–27. [CrossRef] [PubMed] [Google Scholar]
  30. Shahian DM, O’brien SM, Filardo G, et al. The society of thoracic Surgeons 2008 cardiac surgery risk models: Part 1—Coronary artery bypass grafting surgery. Ann Thorac Surg. 2009;88(Suppl 1):S2–S22. [CrossRef] [PubMed] [Google Scholar]
  31. Lancaster TS, Schill MR, Greenberg JW, et al. Long-term survival prediction for coronary artery bypass grafting: Validation of the ASCERT model compared with the society of thoracic surgeons predicted risk of mortality. Ann Thorac Surg. 2018;105:1336–43. [CrossRef] [PubMed] [Google Scholar]
  32. Shahian DM, He X, O’Brien SM, et al. Development of a clinical registry-based 30-day readmission measure for coronary artery bypass grafting surgery. Circulation. 2014;130:399–409. [CrossRef] [PubMed] [Google Scholar]
  33. Ong FS, Das K, Wang J, et al. Personalized medicine and pharmacogenetic biomarkers: Progress in molecular oncology testing. Expert Rev Mol Diagn. 2012;12:593–602. [CrossRef] [PubMed] [Google Scholar]
  34. Corral-Velez V, Lopez-Delgado JC, Betancur-Zambrano NL, et al. The inflammatory response in cardiac surgery: An overview of the pathophysiology and clinical implications. Inflamm Allergy Drug Targets. 2015;13:367–70. [CrossRef] [PubMed] [Google Scholar]
  35. Larmann J, Theilmeier G Inflammatory response to cardiac surgery: Cardiopulmonary bypass versus non-cardiopulmonary bypass surgery. Best Pract Res Clin Anaesthesiol. 2004;18:425–38. [CrossRef] [PubMed] [Google Scholar]
  36. Chew MS, Brandslund I, Brix-Christensen V, et al. Tissue injury and the inflammatory response to pediatric cardiac surgery with cardiopulmonary bypass: A descriptive study. Anesthesiology. 2001;94:745–53; discussion 5A. [CrossRef] [PubMed] [Google Scholar]
  37. Askevold ET, Gullestad L, Dahl CP, et al. Interleukin-6 signaling, soluble glycoprotein 130, and inflammation in heart failure. Curr Heart Fail Rep. 2014;11:146–55. [CrossRef] [PubMed] [Google Scholar]
  38. DiMaria-Ghalili RA, Sullivan-Marx EM, Compher C Inflammation, functional status, and weight loss during recovery from cardiac surgery in older adults: A pilot study. Biol Res Nurs. 2014;16:344–52. [CrossRef] [PubMed] [Google Scholar]
  39. Rallidis L, Zolindaki M, Pentzeridis P, et al. Raised concentrations of macrophage colony stimulating factor in severe unstable angina beyond the acute phase are strongly predictive of long term outcome. Heart. 2004;90:25–9. [CrossRef] [Google Scholar]
  40. Gallagher P, Lowe G, Fitzgerald T, et al. Association of IL-10 polymorphism with severity of illness in community acquired pneumonia. Thorax. 2003;58:154–6. [CrossRef] [PubMed] [Google Scholar]
  41. Niemand C, Nimmesgern A, Haan S, et al. Activation of STAT3 by IL-6 and IL-10 in primary human macrophages is differentially modulated by suppressor of cytokine signaling 3. J Immunol. 2003;170:3263–72. [CrossRef] [PubMed] [Google Scholar]
  42. Takanashi S, Hasegawa Y, Kanehira Y, et al. Interleukin‐10 level in sputum is reduced in bronchial asthma, COPD and in smokers. Eur Respir J. 1999;14:309–14. [CrossRef] [PubMed] [Google Scholar]
  43. Anguera I, Miranda-Guardiola F, Bosch X, et al. Elevation of serum levels of the anti-inflammatory cytokine interleukin-10 and decreased risk of coronary events in patients with unstable angina. Am Heart J. 2002;144:811–7. [CrossRef] [PubMed] [Google Scholar]
  44. Waehre T, Halvorsen B, Damås J, et al. Inflammatory imbalance between IL‐10 and TNFα in unstable angina potential plaque stabilizing effects of IL‐10. Eur J Clin Invest. 2002;32:803–10. [CrossRef] [PubMed] [Google Scholar]
  45. Verma SK, Girikipathi VN, Krishnamurthy P, et al. Interleukin-10 inhibits bone marrow fibroblast progenitor cell-mediated cardiac fibrosis in pressure-overloaded myocardium. Circulation. 2017;136:940–53. [CrossRef] [PubMed] [Google Scholar]
  46. Chalikias GK, Tziakas DN, Kaski JC, et al. Interleukin-18/interleukin-10 ratio is an independent predictor of recurrent coronary events during a 1-year follow-up in patients with acute coronary syndrome. Int J Cardiol. 2007;117:333–9. [CrossRef] [PubMed] [Google Scholar]
  47. Izumi T, Nishii M Diagnostic and prognostic biomarkers in acute myocarditis. Herz. 2012;37:627–31. [CrossRef] [PubMed] [Google Scholar]
  48. Brown JR, Jacobs JP, Alam SS, et al. Utility of biomarkers to improve prediction of readmission or mortality after cardiac surgery. Ann Thorac Surg. 2018;106:1294–301. [CrossRef] [PubMed] [Google Scholar]
  49. Jacobs JP, Alam SS, Owens SL, et al. The association between novel biomarkers and 1-year readmission or mortality after cardiac surgery. Ann Thorac Surg. 2018;106:1122–8. [CrossRef] [PubMed] [Google Scholar]
  50. National Center for Health Statistics. Health, United States, 2016: With Chartbook on Long-term Trends in Health. Hyattsville, MD. 2017. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.